ERBB2 and neoplasm: Moreover, in this model, repeated dosing of anti-HER2 rat IgEs to immunocompetent rats did not trigger severe toxicity or overt signs of anaphylaxis, in line with observations for IgE antibodies that target other tumor-associated antigens [19, 20, 35].